Insulin

What is Insulin?#

Insulin is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

Mechanism of Action#

Insulin binds a preformed disulfide-linked α2β2 receptor tyrosine kinase (IR) at the cell surface. Ligand binding reorients the ectodomain, relieves autoinhibition, and induces trans-autophosphorylation on activation-loop and C-terminal tyrosines of the β subunits, creating PTB/SH2 docking sites for substrates including IRS1/2, Shc, SH2B2, and Cbl.

Canonical metabolic signaling: Tyrosine-phosphorylated IRS recruits class I PI3K (p85–p110), generating PIP3 that recruits PDK1 and Akt to the membrane; PDK1 (Thr308) and mTORC2 (Ser473) activate Akt. Akt phosphorylates key substrates: TBC1D4/AS160 to disinhibit Rab GTPases controlling GLUT4 vesicle trafficking; GSK3 to relieve inhibition of glycogen synthase; TSC2 and PRAS40 to activate mTORC1 leading to S6K and lipogenic programs (e.g., SREBP1c); and FoxO transcription factors to suppress gluconeogenic gene expression.

Mitogenic signaling: Phospho‑Shc recruits Grb2–SOS to activate Ras, triggering the Raf–MEK–ERK cascade that regulates gene expression underlying growth and differentiation (parallel to metabolic signaling).

GLUT4 trafficking machinery: Insulin increases plasma-membrane GLUT4 in adipocytes and myofibers by accelerating exocytosis of GLUT4 storage vesicles. Downstream of Akt, phosphorylation of TBC1D4/AS160 permits activation of Rab8a (muscle) and Rab10 (adipose) and engages RalA/exocyst; additional regulators include SNARE-associated factors such as synip and CDP138 that facilitate vesicle docking and fusion. In adipocytes, a complementary APS/CAP/Cbl pathway in lipid rafts signals via Crk→C3G→TC10 to recruit the exocyst and aid docking.

Metabolic enzyme targets and programs:

• Glycogen synthesis: Akt inhibits GSK3, decreasing inhibitory phosphorylation of glycogen synthase; insulin also promotes PP1-mediated dephosphorylation of glycogen synthase via scaffolds (e.g., PTG), together increasing glycogen storage.
• Lipid metabolism: mTORC1 activation enables S6K and SREBP1c processing; SREBP1c upregulates lipogenic enzymes including ACC. In adipocytes, Akt activates PDE3B to lower cAMP and suppress PKA-dependent lipolysis, reducing fatty acid release.
• Transcriptional control: Akt-mediated phosphorylation excludes FoxO1/3 from the nucleus, rapidly repressing hepatic gluconeogenic genes (e.g., PEPCK, G6Pase). mTORC1 further promotes SREBP1c-dependent lipogenic gene expression via lipin-1 phosphorylation and associated trafficking steps.

mTORC1 engagement and feedback: Akt phosphorylation of TSC2 disinhibits Rheb and relieves PRAS40-mediated inhibition of mTORC1, enhancing protein synthesis and lipogenesis. Negative feedback via mTORC1/S6K promotes inhibitory serine phosphorylation and degradation of IRS, attenuating upstream signaling.

Termination and negative regulation: Signaling is curtailed by PIP3 phosphatases PTEN and SHIP2; dephosphorylation of Akt by PP2A and PHLPP; protein tyrosine phosphatases such as PTP1B that dephosphorylate IR; receptor internalization and degradation; and stress-kinase pathways (JNK, IKKβ) that phosphorylate IRS serine residues to impair signaling.

Tissue-specific endpoints:

• Skeletal muscle: Rapid GLUT4 translocation elevates glucose uptake; Akt/GSK3 signaling enhances glycogen synthesis; mTORC1 supports protein synthesis.
• Adipose tissue: GLUT4 translocation increases glucose uptake for glycerol-3-phosphate and lipid synthesis; Akt→PDE3B suppresses lipolysis; CAP/Cbl/TC10 contributes to GLUT4 docking.
• Liver: Akt inhibits FoxO to suppress gluconeogenesis; mTORC1/SREBP1c promotes de novo lipogenesis; Akt/GSK3 favors glycogen synthesis.

Together these pathways explain insulin’s coordinated control of vesicle trafficking, enzyme activity, and gene expression to maintain glucose and lipid homeostasis, and how feedback and phosphatases temper signaling to prevent overstimulation.

Therapeutic Applications#

Therapeutic applications of insulin span established metabolic indications and emerging neurometabolic and tissue-repair uses. Below we summarize preclinical and clinical evidence with specific outcomes.

Glycemic control in diabetes (T1D/T2D)

• Type 1 diabetes, intensive therapy: The DCCT randomized 1,441 participants to intensive insulin therapy versus conventional therapy for a mean 6.5 years. Intensive therapy (HbA1c ≈7% vs ≈9%) reduced microvascular complications substantially: retinopathy progression decreased 76% in the primary prevention cohort and 54% in the secondary cohort; development of microalbuminuria decreased ~39% and clinical albuminuria ~56%; confirmed clinical neuropathy decreased up to ~69%. Hypoglycemia increased during intensive therapy. Benefits persisted during EDIC despite later convergence of HbA1c, demonstrating “metabolic memory.”
• Long-term cardiovascular outcomes in T1D: Over ~30 years of DCCT/EDIC follow-up, prior intensive therapy reduced any cardiovascular disease by 30% (95% CI 7–48; P=0.016) and major cardiovascular events by ~32% (P≈0.07). Benefits were mediated by lower HbA1c during DCCT.
• Type 2 diabetes, intensive control and legacy effect (UKPDS): In the sulfonylurea/insulin group (median HbA1c 7.0% vs 7.9% over ~10 years), microvascular disease fell by 25% and any diabetes-related endpoint by 12% during the trial; after ~10 years post-trial, legacy benefits emerged with myocardial infarction reduced by ~15% and all-cause mortality by ~13%.

Glycemic control in critical illness (ICU)

• Across 26 trials (n≈13,567), intensive insulin therapy conferred no overall mortality benefit versus conventional control (pooled RR 0.93, 95% CI 0.83–1.04) but increased severe hypoglycemia sixfold (RR ≈6.0). Possible benefit was confined to surgical ICU subsets; overall effect and safety favor avoiding overly tight targets.

Cardiovascular adjuncts: glucose–insulin–potassium (GIK)

• Acute MI (CREATE‑ECLA and meta-analyses): The large CREATE‑ECLA trial showed no 30‑day mortality benefit (deaths 10.0% GIK vs 9.7% control; P=0.45). Meta-analyses pooling tens of thousands of patients likewise found no reduction in 30‑day mortality (e.g., OR 1.05, 95% CI 0.97–1.14). Early hyperglycemia and fluid load in GIK arms were associated with adverse early signals.
• Very-early EMS GIK (IMMEDIATE): Designed to test prehospital administration on progression to MI and on composites including cardiac arrest or in-hospital death and infarct size. The retrieved text describes endpoints and design but does not provide definitive numeric effects; timing may be critical. (selker2012…myocardialmetabolic pages 1-3)

Electrolyte emergencies: hyperkalemia shift therapy

• Intravenous insulin with glucose rapidly shifts K+ intracellularly. A systematic review and ED cohorts indicate typical mean serum K+ reduction ≈0.8–1.1 mmol/L at ~60 minutes after 10 units IV regular insulin; lowering the dose (<10 U) modestly attenuates K+ reduction (e.g., 0.94 vs 1.11 mmol/L) but reduces hypoglycemia risk. Hypoglycemia occurs in ~10–21% of treated episodes, peaking between 60 and 150 minutes (often ~90 minutes), mandating glucose monitoring for ≥3 hours.

Neurologic applications: intranasal insulin

• Mild cognitive impairment/Alzheimer disease (pilot RCT): In a 4‑month randomized, double-blind trial (n=104; 20 IU/day or 40 IU/day vs placebo), intranasal insulin improved delayed story recall at 20 IU (P<.05; Cohen f ≈0.36) and preserved study partner–rated function (DSRS) for both doses; ADAS‑Cog decline was attenuated in insulin groups, and FDG‑PET showed reduced progression of cortical hypometabolism. Group-level CSF Aβ42 and tau/Aβ42 did not change significantly, though exploratory correlations linked biomarker changes to cognitive/function outcomes. Safety was acceptable over 4 months.
• Preclinical neuroprotection: In rodent models, intranasal insulin prevented anesthesia-induced cognitive impairment, reduced tau hyperphosphorylation and neuroinflammation, and improved spatial learning (e.g., Morris water maze), supporting mechanistic plausibility for CNS benefits.

Tissue repair: topical/local insulin for wound healing

• Diabetic wound healing (RCT + translational data): A double‑blind, placebo‑controlled clinical trial reported that daily topical insulin cream “markedly improved wound healing” in diabetic foot ulcers. In parallel animal studies, topical insulin normalized delayed healing and enhanced insulin‑signaling pathways (IR/IRS‑1/2, AKT/ERK), VEGF, and eNOS in wound tissue.

Structured summary of applications and outcomes

Conclusions

• Insulin’s foundational role in chronic glycemic control translates into large and durable reductions in microvascular complications and long-term cardiovascular benefit in type 1 diabetes, with a legacy effect also evident in type 2 diabetes. In critically ill populations, tight glycemic control with insulin increases hypoglycemia and has not shown overall mortality benefit, arguing for moderated targets. As a cardiovascular adjunct in AMI, GIK has not improved mortality in modern trials. For hyperkalemia, IV insulin with dextrose reliably lowers K+ within 1–2 hours but requires vigilant hypoglycemia prevention and monitoring. Intranasal insulin shows short‑term cognitive and functional benefits in MCI/AD with supportive neuroimaging signals and preclinical mechanistic data; definitive large-scale clinical efficacy remains to be established. Topical insulin demonstrates promise in enhancing diabetic wound healing with supportive molecular findings.

Research Evidence Quality#

Scope and overall quality of evidence Insulin is essential therapy for type 1 diabetes (T1D) and frequently used in type 2 diabetes (T2D), with a large but heterogeneous evidence base. The strongest randomized evidence demonstrates that intensive insulin-based glycemic control reduces microvascular complications in T1D and that early intensive control confers durable cardiovascular benefit over decades; in T2D, large trials and meta-analyses show neutral cardiovascular effects and increased hypoglycemia relative to noninsulin therapies, while dedicated cardiovascular outcome trials (CVOTs) of modern basal insulins establish cardiovascular safety but not superiority on major adverse cardiovascular events (MACE) versus comparators at similar glycemic control (treat-to-target).

Type 1 diabetes

• Microvascular outcomes: Intensive insulin therapy in DCCT markedly reduced development and progression of retinopathy, nephropathy, and neuropathy; EDIC follow-up showed persistent “metabolic memory” with sustained reductions in retinopathy progression despite later convergence of HbA1c.
• Macrovascular outcomes: Over ~30 years of DCCT/EDIC, prior intensive insulin therapy reduced any cardiovascular disease by about one-third, indicating long-term macrovascular benefit attributable to earlier glycemic control.
• Safety and patient-centered considerations: Intensive therapy is associated with weight gain and hypoglycemia risks; contemporary adjunct agents (e.g., SGLT2 inhibitors, GLP-1 receptor agonists) lack T1D CVOTs and carry their own risks, underscoring evidence gaps in modern regimens layered on insulin.

Type 2 diabetes

• Intensive glycemic control strategies and insulin: Meta-analysis of randomized trials found no reduction in all-cause or cardiovascular mortality, and no clear macrovascular benefit with insulin versus oral agents or diet/placebo; insulin substantially increased severe hypoglycemia versus oral agents. Narrative syntheses highlight heterogeneous trial results across risk profiles, with some studies reporting neutral or even harmful mortality signals under intensive strategies in high-risk cohorts (contextualized in reviews).
• Microvascular outcomes: In T2D, intensive glycemic control confers modest microvascular benefits in some domains, but the insulin-attributable effect on hard microvascular endpoints across trials is limited and inconsistent; the meta-analysis noted a laser photocoagulation signal largely from a single trial and emphasized methodological constraints.
• Safety: Insulin use increases hypoglycemia risk compared with oral therapies; severe hypoglycemia is a key driver of emergency care utilization, particularly in older adults.

Basal insulin cardiovascular outcome trials (glargine, degludec)

• Insulin glargine (ORIGIN): In older individuals with dysglycemia, targeting fasting glucose ≤95 mg/dL with glargine for >6 years had a neutral effect on MACE and cancer incidence, with modest weight gain and increased severe hypoglycemia versus standard care.
• Insulin degludec vs glargine (DEVOTE): Treat-to-target CVOT showed noninferiority for MACE and a significantly lower rate of severe hypoglycemia with degludec relative to glargine; secondary analyses found severe hypoglycemia was temporally associated with elevated all-cause mortality risk, although causality cannot be inferred.
• Implications: Together, these CVOTs support cardiovascular safety of modern basal analogs and highlight hypoglycemia differences across insulins at comparable HbA1c.

Pregnancy/gestational diabetes

• We were unable to retrieve citable randomized comparisons of insulin vs metformin for gestational diabetes mellitus (GDM) within the accessible context for this analysis. Contemporary guidelines and trials outside the available citations generally compare maternal glycemic control and neonatal outcomes (e.g., hypoglycemia, macrosomia, NICU admission). Because these data were not captured in the current evidence set, conclusions for pregnancy must be considered incomplete here.

Extent of evidence and what it means

• T1D: High-quality, long-duration RCT evidence (DCCT/EDIC) establishes intensive insulin therapy as disease-modifying for microvascular outcomes and supportive of long-term cardiovascular benefit from early glycemic control (metabolic memory), albeit with increased hypoglycemia and weight gain.
• T2D: The randomized evidence base indicates that, beyond glycemic lowering, insulin has not demonstrated cardiovascular or mortality benefit versus noninsulin comparators and incurs higher severe hypoglycemia risk; microvascular benefits are limited and methodologically constrained across trials.
• Basal analog CVOTs: Robust CV safety has been demonstrated for glargine and degludec; degludec reduces severe hypoglycemia relative to glargine under treat-to-target conditions, informing agent selection when insulin is indicated.

Key limitations, evidence gaps, and criticisms

• External validity and era effects: Foundational T1D trials predate modern diabetes technologies (CGM, automated insulin delivery) and contemporary adjunct agents, limiting direct generalizability to current care paradigms.

• Comparator limitations in T2D: Many trials compared insulin to older oral agents or standard care, not to modern cardioprotective therapies (GLP-1 receptor agonists, SGLT2 inhibitors), constraining inferences about relative clinical value in today’s therapeutic landscape.

• Outcome neutrality for cardiovascular endpoints: Insulin-based strategies in T2D have not consistently improved MACE or mortality in randomized evidence, and observational signals of harm are confounded by indication and disease severity, complicating causal interpretation.

• Hypoglycemia and mortality: Severe hypoglycemia is consistently more frequent with insulin than with oral agents and is temporally associated with increased mortality risk in high-risk T2D, highlighting a critical safety concern and the need for hypoglycemia-minimizing regimens.

• Basal insulin CVOT scope: Dedicated CVOTs exist only for basal analogs (glargine, degludec); no CVOTs evaluate prandial or premixed insulins, and treat-to-target designs may attenuate detection of between-treatment differences mediated by glycemia.

• Pregnancy: Randomized, long-term offspring safety and maternal cardiovascular outcome data comparing insulin with alternatives (e.g., metformin) are limited in the currently accessible evidence set; thus, guidance relies on broader literature outside this context (partial answer).

• In T1D, intensive insulin therapy provides high-certainty reductions in microvascular complications and durable cardiovascular benefit from early control, offset by hypoglycemia and weight gain risks.

• In T2D, insulin reliably lowers glucose but has not demonstrated cardiovascular or survival advantages over noninsulin therapies, and it increases severe hypoglycemia; modern basal analogs are cardiovascularly safe, with degludec reducing severe hypoglycemia vs glargine at similar HbA1c.

• Major gaps include direct comparisons to contemporary cardioprotective agents, CVOTs for non-basal insulins, and robust pregnancy/offspring outcome data within the present evidence set.

Evidence Gaps and Limitations#

The current evidence base for Insulin consists primarily of preclinical studies. Key limitations include:

• No completed randomized controlled trials in humans
• Most data derived from animal models, limiting direct translatability
• Publication bias may favor positive results
• Long-term safety data in humans is not available
• Optimal dosing for human applications has not been established

Key Research Findings#

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, published in New England Journal of Medicine (The Diabetes Control and Complications Trial Research Group, 1993; PMID: 8366922):

• The study demonstrated retinopathy progression decreased of 76% and 54%
• Landmark RCT in 1441 T1D patients showing intensive insulin therapy reduced microvascular complications by 26-63% over 6.5 years versus conventional therapy

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), published in The Lancet (UK Prospective Diabetes Study (UKPDS) Group, 1998; PMID: 9742976):

• The study showed microvascular disease reduced by 25% with intensive versus conventional therapy
• RCT in 3867 newly diagnosed T2D patients showing intensive glucose control reduced microvascular complications by 25% over median 10 years

Related Reading#

• Insulin research studies and evidence
• Insulin dosing protocols
• Insulin side effects profile
• Semaglutide research guide
• Tirzepatide research guide